Esperion(US:ESPR) Newsfilter·2025-03-03 13:00Core Insights - Esperion Therapeutics has entered into a license and distribution agreement with CSL Seqirus for the exclusive rights to commercialize NEXLETOL® and NEXLIZET® in Australia and New Zealand [1][4] - The partnership aims to address the significant burden of cardiovascular disease in these regions, where it affects 1.2 million people in Australia and 175,000 adults in New Zealand [2][3] Agreement Details - Under the agreement, Esperion will receive an upfront payment and milestone payments of up to approximately $5 million, and will supply finished products to CSL Seqirus at a profitable transfer price [5] - CSL Seqirus will handle the commercialization aspects, including regulatory approval, reimbursement, and marketing [4] Product Indications - NEXLIZET and NEXLETOL are indicated for reducing LDL-C cholesterol and the risk of cardiovascular disease in adults who cannot take statin therapy, as well as for adults with primary hyperlipidemia [6][8] Company Background - Esperion Therapeutics is focused on developing non-statin medications for patients at risk of cardiovascular disease, supported by the CLEAR Cardiovascular Outcomes Trial involving nearly 14,000 patients [17][18] - CSL Seqirus is a major player in the influenza vaccine market and is committed to providing innovative pharmaceuticals for various health conditions, including cardiovascular disease [15][16]